Literature DB >> 17568031

Clinical practice. Follow-up of patients with early breast cancer.

Daniel F Hayes1.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2007        PMID： 17568031     DOI： 10.1056/NEJMcp067260

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  15 in total

1.  Interdisciplinary GoR level III Guidelines for the Diagnosis, Therapy and Follow-up Care of Breast Cancer: Short version - AWMF Registry No.: 032-045OL AWMF-Register-Nummer: 032-045OL - Kurzversion 3.0, Juli 2012.

Authors:  R Kreienberg; U-S Albert; M Follmann; I B Kopp; T Kühn; A Wöckel
Journal:  Geburtshilfe Frauenheilkd       Date:  2013-06       Impact factor: 2.915

2.  Accuracy and outcomes of screening mammography in women with a personal history of early-stage breast cancer.

Authors:  Nehmat Houssami; Linn A Abraham; Diana L Miglioretti; Edward A Sickles; Karla Kerlikowske; Diana S M Buist; Berta M Geller; Hyman B Muss; Les Irwig
Journal:  JAMA       Date:  2011-02-23       Impact factor: 56.272

3.  Follow-up Reality for Breast Cancer Patients - Standardised Survey of Patients and Physicians and Analysis of Treatment Data.

Authors:  S Feiten; J Dünnebacke; V Friesenhahn; J Heymanns; H Köppler; R Meister; J Thomalla; C van Roye; D Wey; R Weide
Journal:  Geburtshilfe Frauenheilkd       Date:  2016-05       Impact factor: 2.915

4.  Quality of cancer follow-up care: a focus on Latina breast cancer survivors.

Authors:  Monica Rosales; Kimlin Ashing; Anna Napoles
Journal:  J Cancer Surviv       Date:  2014-02-22       Impact factor: 4.442

5.  20-Year Risks of Breast-Cancer Recurrence after Stopping Endocrine Therapy at 5 Years.

Authors:  Hongchao Pan; Richard Gray; Jeremy Braybrooke; Christina Davies; Carolyn Taylor; Paul McGale; Richard Peto; Kathleen I Pritchard; Jonas Bergh; Mitch Dowsett; Daniel F Hayes
Journal:  N Engl J Med       Date:  2017-11-09       Impact factor: 91.245

6.  Cytochrome P450 2D6 activity predicts discontinuation of tamoxifen therapy in breast cancer patients.

Authors:  J M Rae; M J Sikora; N L Henry; L Li; S Kim; S Oesterreich; T C Skaar; A T Nguyen; Z Desta; A M Storniolo; D A Flockhart; D F Hayes; V Stearns
Journal:  Pharmacogenomics J       Date:  2009-05-05       Impact factor: 3.550

7.  Second non-breast primary cancer following adjuvant therapy for early breast cancer: a report from the International Breast Cancer Study Group.

Authors:  Lorenzo Gianni; Shari Gelber; Alberto Ravaioli; Karen N Price; Ilaria Panzini; Manuela Fantini; Monica Castiglione-Gertsch; Olivia Pagani; Edda Simoncini; Richard D Gelber; Alan S Coates; Aron Goldhirsch
Journal:  Eur J Cancer       Date:  2008-12-04       Impact factor: 9.162

8.  Risk factors for second screen-detected or interval breast cancers in women with a personal history of breast cancer participating in mammography screening.

Authors:  Nehmat Houssami; Linn A Abraham; Karla Kerlikowske; Diana S M Buist; Les Irwig; Janie Lee; Diana L Miglioretti
Journal:  Cancer Epidemiol Biomarkers Prev       Date:  2013-03-19       Impact factor: 4.254

9.  Medication use trajectories of postmenopausal breast cancer survivors and matched cancer-free controls.

Authors:  Kathy Pan; Rowan T Chlebowski; Michael S Simon; Roberta M Ray; Jennifer Livaudais-Toman; Shannon D Sullivan; Marcia L Stefanick; Robert B Wallace; Meryl LeBoff; Elizabeth Carhart Bluhm; Electra D Paskett
Journal:  Breast Cancer Res Treat       Date:  2016-04-13       Impact factor: 4.872

10.  Effects of vaginal estrogens on serum estradiol levels in postmenopausal breast cancer survivors and women at risk of breast cancer taking an aromatase inhibitor or a selective estrogen receptor modulator.

Authors:  Shannon Wills; Anita Ravipati; Padmaja Venuturumilli; Cynthia Kresge; Elizabeth Folkerd; Mitch Dowsett; Daniel F Hayes; David A Decker
Journal:  J Oncol Pract       Date:  2012-02-07       Impact factor: 3.840
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.